Dainippon Sumitomo Pharma (DSP) has set up a wholly owned subsidiary, Sunovion Pharmaceuticals Asia Pacific Pte Ltd, in Singapore as a base of operations in Southeast Asia.
DSP said it is progressing its global expansion with its global strategic product, antipsychotic lurasidone hydrochloride (generic name) at the core. As a part of this effort, DSP has considered extending commercial operations for lurasidone hydrochloride to countries in Southeast Asia where growth is expected in the mid-to long term.
DSP said it will first promote business operations such as obtaining approval for and marketing lurasidone hydrochloride in Southeast Asia through partnerships with local companies. Using Singapore as a base of operations, DSP will consider successive expansion of its product lineups in Southeast Asia and additionally business expansion into neighboring countries such as Australia.